Mantra Bio announced today that it has raised $9 million in Series A-2 funding to further develop its primary tailored exosome medicines technology. In the fundraising round, Samsung Securities joined existing investors such as 8VC, Viking Global Investors, Illumina, BoxGroup, and Allen & Company. The entire Series A capital for the company is $34 million, including a $25 million Series A-1.
Mantra Bio will be able to move our primary development candidate via IND enabling investigations thanks to the new Series A-2 funding. The backing of Samsung Securities and our existing investors demonstrates a significant belief in the potential of our platform, therapeutic pipeline plan, and progress.
Mantra Bio is developing next generation, targeted therapeutics based on its proprietary exosome engineering platform, REVEAL™. The REVEAL™ platform, which integrates computational biology and bench lab automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics can be reproducibly made at high purity, consistency, and yield. The company’s initial pipeline includes engineered exosome therapeutics in the areas of ophthalmology and infectious diseases.
